Drug treatment for spinal muscular atrophy type I.

Renske I. Wadman, Wendy M J Bosboom, W. Ludo van der Pol, Leonard H. van den Berg, John H J Wokke, Susan T. Iannaccone, Alexander F F J E Vrancken

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells of the spinal cord, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the course of the disease. This is an update of a review first published in 2009. To evaluate whether drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA types II and III is the topic of a separate updated Cochrane review. We searched the Cochrane Neuromuscular Disease Group Specialized Register (8 March 2011), CENTRAL (The Cochrane Library 2011, Issue 1), MEDLINE (January 1991 to February 2011), EMBASE (January 1991 to February 2011) and ISI Web of Knowledge (January 1991 to 8 March 2011). We searched the Clinical Trials Registry of the U.S. National Institute of Health (www.ClinicalTrials.gov) (8 March 2011) to identify additional trials that had not yet been published. We sought all randomised or quasi-randomised trials that examined the efficacy of drug treatment for SMA type I. Participants had to fulfil the clinical criteria and have a deletion or mutation of the SMN1 gene (5q11.2-13.2) confirmed by genetic analysis.The primary outcome measure was time from birth until death or full time ventilation. Secondary outcome measures were development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Two authors (RW and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies, pooled relative risks and standardised mean differences were to be calculated to assess treatment efficacy. One small randomised controlled study comparing riluzole treatment to placebo for 10 SMA type 1 children was identified and included in the original review. No further trials were identified for the update in 2011. Regarding the primary outcome measure, three of seven children treated with riluzole were still alive at the ages of 30, 48 and 64 months, whereas all three children in the placebo group died; but the difference was not statistically significant. Regarding the secondary outcome measures, none of the children in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. For several reasons the overall quality of the study was low, mainly because the study was too small to detect an effect and because of baseline differences. Follow-up of the 10 included children was complete. No drug treatment for SMA type I has been proven to have significant efficacy.

Original languageEnglish (US)
JournalCochrane database of systematic reviews (Online)
Volume4
StatePublished - 2012

Fingerprint

Spinal Muscular Atrophies of Childhood
Riluzole
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Placebos
Therapeutics
Anterior Horn Cells
Spinal Muscular Atrophy
Neuromuscular Diseases
Sequence Deletion
Muscle Weakness
National Institutes of Health (U.S.)
MEDLINE
Libraries
Ventilation
Registries
Disease Progression
Spinal Cord
Clinical Trials
Parturition

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wadman, R. I., Bosboom, W. M. J., van der Pol, W. L., van den Berg, L. H., Wokke, J. H. J., Iannaccone, S. T., & Vrancken, A. F. F. J. E. (2012). Drug treatment for spinal muscular atrophy type I. Cochrane database of systematic reviews (Online), 4.

Drug treatment for spinal muscular atrophy type I. / Wadman, Renske I.; Bosboom, Wendy M J; van der Pol, W. Ludo; van den Berg, Leonard H.; Wokke, John H J; Iannaccone, Susan T.; Vrancken, Alexander F F J E.

In: Cochrane database of systematic reviews (Online), Vol. 4, 2012.

Research output: Contribution to journalArticle

Wadman, RI, Bosboom, WMJ, van der Pol, WL, van den Berg, LH, Wokke, JHJ, Iannaccone, ST & Vrancken, AFFJE 2012, 'Drug treatment for spinal muscular atrophy type I.', Cochrane database of systematic reviews (Online), vol. 4.
Wadman RI, Bosboom WMJ, van der Pol WL, van den Berg LH, Wokke JHJ, Iannaccone ST et al. Drug treatment for spinal muscular atrophy type I. Cochrane database of systematic reviews (Online). 2012;4.
Wadman, Renske I. ; Bosboom, Wendy M J ; van der Pol, W. Ludo ; van den Berg, Leonard H. ; Wokke, John H J ; Iannaccone, Susan T. ; Vrancken, Alexander F F J E. / Drug treatment for spinal muscular atrophy type I. In: Cochrane database of systematic reviews (Online). 2012 ; Vol. 4.
@article{2b969e02eb1d4aaa810cb9402d4c6e8f,
title = "Drug treatment for spinal muscular atrophy type I.",
abstract = "Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells of the spinal cord, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the course of the disease. This is an update of a review first published in 2009. To evaluate whether drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA types II and III is the topic of a separate updated Cochrane review. We searched the Cochrane Neuromuscular Disease Group Specialized Register (8 March 2011), CENTRAL (The Cochrane Library 2011, Issue 1), MEDLINE (January 1991 to February 2011), EMBASE (January 1991 to February 2011) and ISI Web of Knowledge (January 1991 to 8 March 2011). We searched the Clinical Trials Registry of the U.S. National Institute of Health (www.ClinicalTrials.gov) (8 March 2011) to identify additional trials that had not yet been published. We sought all randomised or quasi-randomised trials that examined the efficacy of drug treatment for SMA type I. Participants had to fulfil the clinical criteria and have a deletion or mutation of the SMN1 gene (5q11.2-13.2) confirmed by genetic analysis.The primary outcome measure was time from birth until death or full time ventilation. Secondary outcome measures were development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Two authors (RW and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies, pooled relative risks and standardised mean differences were to be calculated to assess treatment efficacy. One small randomised controlled study comparing riluzole treatment to placebo for 10 SMA type 1 children was identified and included in the original review. No further trials were identified for the update in 2011. Regarding the primary outcome measure, three of seven children treated with riluzole were still alive at the ages of 30, 48 and 64 months, whereas all three children in the placebo group died; but the difference was not statistically significant. Regarding the secondary outcome measures, none of the children in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. For several reasons the overall quality of the study was low, mainly because the study was too small to detect an effect and because of baseline differences. Follow-up of the 10 included children was complete. No drug treatment for SMA type I has been proven to have significant efficacy.",
author = "Wadman, {Renske I.} and Bosboom, {Wendy M J} and {van der Pol}, {W. Ludo} and {van den Berg}, {Leonard H.} and Wokke, {John H J} and Iannaccone, {Susan T.} and Vrancken, {Alexander F F J E}",
year = "2012",
language = "English (US)",
volume = "4",
journal = "The Cochrane database of systematic reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Drug treatment for spinal muscular atrophy type I.

AU - Wadman, Renske I.

AU - Bosboom, Wendy M J

AU - van der Pol, W. Ludo

AU - van den Berg, Leonard H.

AU - Wokke, John H J

AU - Iannaccone, Susan T.

AU - Vrancken, Alexander F F J E

PY - 2012

Y1 - 2012

N2 - Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells of the spinal cord, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the course of the disease. This is an update of a review first published in 2009. To evaluate whether drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA types II and III is the topic of a separate updated Cochrane review. We searched the Cochrane Neuromuscular Disease Group Specialized Register (8 March 2011), CENTRAL (The Cochrane Library 2011, Issue 1), MEDLINE (January 1991 to February 2011), EMBASE (January 1991 to February 2011) and ISI Web of Knowledge (January 1991 to 8 March 2011). We searched the Clinical Trials Registry of the U.S. National Institute of Health (www.ClinicalTrials.gov) (8 March 2011) to identify additional trials that had not yet been published. We sought all randomised or quasi-randomised trials that examined the efficacy of drug treatment for SMA type I. Participants had to fulfil the clinical criteria and have a deletion or mutation of the SMN1 gene (5q11.2-13.2) confirmed by genetic analysis.The primary outcome measure was time from birth until death or full time ventilation. Secondary outcome measures were development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Two authors (RW and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies, pooled relative risks and standardised mean differences were to be calculated to assess treatment efficacy. One small randomised controlled study comparing riluzole treatment to placebo for 10 SMA type 1 children was identified and included in the original review. No further trials were identified for the update in 2011. Regarding the primary outcome measure, three of seven children treated with riluzole were still alive at the ages of 30, 48 and 64 months, whereas all three children in the placebo group died; but the difference was not statistically significant. Regarding the secondary outcome measures, none of the children in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. For several reasons the overall quality of the study was low, mainly because the study was too small to detect an effect and because of baseline differences. Follow-up of the 10 included children was complete. No drug treatment for SMA type I has been proven to have significant efficacy.

AB - Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells of the spinal cord, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the course of the disease. This is an update of a review first published in 2009. To evaluate whether drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA types II and III is the topic of a separate updated Cochrane review. We searched the Cochrane Neuromuscular Disease Group Specialized Register (8 March 2011), CENTRAL (The Cochrane Library 2011, Issue 1), MEDLINE (January 1991 to February 2011), EMBASE (January 1991 to February 2011) and ISI Web of Knowledge (January 1991 to 8 March 2011). We searched the Clinical Trials Registry of the U.S. National Institute of Health (www.ClinicalTrials.gov) (8 March 2011) to identify additional trials that had not yet been published. We sought all randomised or quasi-randomised trials that examined the efficacy of drug treatment for SMA type I. Participants had to fulfil the clinical criteria and have a deletion or mutation of the SMN1 gene (5q11.2-13.2) confirmed by genetic analysis.The primary outcome measure was time from birth until death or full time ventilation. Secondary outcome measures were development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Two authors (RW and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies, pooled relative risks and standardised mean differences were to be calculated to assess treatment efficacy. One small randomised controlled study comparing riluzole treatment to placebo for 10 SMA type 1 children was identified and included in the original review. No further trials were identified for the update in 2011. Regarding the primary outcome measure, three of seven children treated with riluzole were still alive at the ages of 30, 48 and 64 months, whereas all three children in the placebo group died; but the difference was not statistically significant. Regarding the secondary outcome measures, none of the children in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. For several reasons the overall quality of the study was low, mainly because the study was too small to detect an effect and because of baseline differences. Follow-up of the 10 included children was complete. No drug treatment for SMA type I has been proven to have significant efficacy.

UR - http://www.scopus.com/inward/record.url?scp=84864050619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864050619&partnerID=8YFLogxK

M3 - Article

C2 - 22513939

AN - SCOPUS:84864050619

VL - 4

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

SN - 1361-6137

ER -